Two years of wearing the Viaskin patch for peanut allergy desensitized 81 percent of peanut-allergic children ages 1 to 3,… Read more »
Tag: DBV technologies
Viaskin Peanut Patch Desensitized Most Toddlers in Phase 3 Trial
The Viaskin patch for peanut allergy is showing promise in desensitizing peanut-allergic toddlers in a late-stage trial. After wearing the… Read more »
Allergy News: EpiPen Class Action Can Proceed; DBV Hopeful on Patch
Mylan Loses Bid to Dismiss Lawsuit A U.S. district judge has ruled that a class action lawsuit against Mylan Inc.,… Read more »
DBV Cuts Costs Awaiting FDA; Unveils More Peanut Patch Results
With much of the Food and Drug Administration’s staff working on the coronavirus pandemic, the timeline for reviews of some… Read more »
Study Shows High Costs and Burden of Peanut Allergy
A study of a large U.S. health insurer database reveals the high dollar and health costs for those living with… Read more »
3 in 4 Kids See Benefit From Viaskin Peanut Patch After 3 Years
After three years of using the Viaskin Peanut patch in children ages 4 to 11, more than half (52 percent)… Read more »
Viaskin Peanut Patch Submitted to FDA for Approval Consideration
The manufacturer of the Viaskin Peanut patch has resubmitted its biologics license application (or BLA) to the FDA – in… Read more »
Peanut Allergy Therapies: ICER’s Review Draws Criticism
What do you get when you undertake a cost-benefit analysis of new therapies when prices have yet to be established… Read more »
Viaskin Peanut Patch Back on the FDA Approval Track for Fall 2019
The manufacturer of the Viaskin Peanut patch has announced plans to resubmit its biologics license application (BLA) for the therapy… Read more »
Patch Progress, Peanut OIT in Adults Data Presented at EAACI Meeting
We’re learning more about the two therapies to treat peanut allergies that could soon be available in allergist’s offices in… Read more »